152 related articles for article (PubMed ID: 21636894)
1. Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease.
Lin YC; Perryman AL; Olson AJ; Torbett BE; Elder JH; Stout CD
Acta Crystallogr D Biol Crystallogr; 2011 Jun; 67(Pt 6):540-8. PubMed ID: 21636894
[TBL] [Abstract][Full Text] [Related]
2. Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.
Lin YC; Torbett BE; Elder JH
J Virol; 2010 Jul; 84(13):6799-809. PubMed ID: 20410281
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.
Heaslet H; Lin YC; Tam K; Torbett BE; Elder JH; Stout CD
Retrovirology; 2007 Jan; 4():1. PubMed ID: 17212810
[TBL] [Abstract][Full Text] [Related]
4. Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.
Lin YC; Happer M; Elder JH
J Virol; 2013 Aug; 87(15):8524-34. PubMed ID: 23720716
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
[TBL] [Abstract][Full Text] [Related]
6. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease.
Li M; Morris GM; Lee T; Laco GS; Wong CH; Olson AJ; Elder JH; Wlodawer A; Gustchina A
Proteins; 2000 Jan; 38(1):29-40. PubMed ID: 10651036
[TBL] [Abstract][Full Text] [Related]
7. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus.
Wlodawer A; Gustchina A; Reshetnikova L; Lubkowski J; Zdanov A; Hui KY; Angleton EL; Farmerie WG; Goodenow MM; Bhatt D
Nat Struct Biol; 1995 Jun; 2(6):480-8. PubMed ID: 7664111
[TBL] [Abstract][Full Text] [Related]
8. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.
Lin YC; Beck Z; Lee T; Le VD; Morris GM; Olson AJ; Wong CH; Elder JH
J Virol; 2000 May; 74(10):4710-20. PubMed ID: 10775609
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
[TBL] [Abstract][Full Text] [Related]
10. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
[TBL] [Abstract][Full Text] [Related]
11. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
Beck ZQ; Lin YC; Elder JH
J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
[TBL] [Abstract][Full Text] [Related]
13. Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.
Eche S; Kumar A; Sonela N; Gordon ML
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33805099
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling of the structure of FIV protease.
Gustchina A
Adv Exp Med Biol; 1995; 362():479-84. PubMed ID: 8540361
[No Abstract] [Full Text] [Related]
15. The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts.
Louis JM; Zhang Y; Sayer JM; Wang YF; Harrison RW; Weber IT
Biochemistry; 2011 May; 50(21):4786-95. PubMed ID: 21446746
[TBL] [Abstract][Full Text] [Related]
16. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis.
Schnölzer M; Rackwitz HR; Gustchina A; Laco GS; Wlodawer A; Elder JH; Kent SB
Virology; 1996 Oct; 224(1):268-75. PubMed ID: 8862421
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor.
Laco GS; Schalk-Hihi C; Lubkowski J; Morris G; Zdanov A; Olson A; Elder JH; Wlodawer A; Gustchina A
Biochemistry; 1997 Sep; 36(35):10696-708. PubMed ID: 9271500
[TBL] [Abstract][Full Text] [Related]
18. Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease.
Marie V; Gordon M
J Biomol Struct Dyn; 2022; 40(21):10852-10861. PubMed ID: 34253143
[TBL] [Abstract][Full Text] [Related]
19. Structures of darunavir-resistant HIV-1 protease mutant reveal atypical binding of darunavir to wide open flaps.
Zhang Y; Chang YC; Louis JM; Wang YF; Harrison RW; Weber IT
ACS Chem Biol; 2014 Jun; 9(6):1351-8. PubMed ID: 24738918
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
